5D Library › Biomathematical Models of Sub-Perceptual Tryptamine Pharmacokinetics, 5-HT2A Receptor Desensitisation and Neuroplastic Window Dynamics · 中文

Preface: Writing a Pharmacological Chain as Mathematics

Note

A legal and health note, to be read first. This book presents biomathematics and methodology for teaching and research. It is not medical advice and is not a guide to using anything. The substances it discusses are controlled in most jurisdictions: Malaysia’s Dangerous Drugs Act 1952 (Act 234) lists Psilocybine and Psilocine in Part III of the First Schedule (Government of Malaysia 2006); in China the relevant substances are scheduled as controlled psychotropic substances; and Australia has authorised prescribing by authorised psychiatrists for specified indications since 1 July 2023 (Therapeutic Goods Administration, Australia 2023). Law differs between jurisdictions and changes over time, and readers must establish the law where they are.

This book gives no dose, mass, product, brand, source, means of purchase, route of administration, method of synthesis or course of use. Every concentration, exposure and amount is expressed as a dimensionless ratio to an unspecified reference — the convention established in Volume 8 — so that the structure of the pharmacology can be discussed without supplying a single number anyone could act on. The book does not recommend that anyone use any substance it discusses. People with a personal or family history of psychotic or bipolar disorder, people with cardiovascular disease, pregnant people and minors are the groups ordinarily excluded from clinical research with these substances; this is noted to explain study design, not to imply that anyone else may use them.

A set of claims has taken fairly definite shape in biohacking and self-optimisation circles. Roughly: bring the exposure to a psychedelic tryptamine below the threshold of perception and one obtains the benefits of 5-HT2A agonism — a rise in the entropy of whole-brain functional connectivity, an open window of neuroplasticity — without any noticeable experience; and by spacing the doses out one avoids the tolerance caused by receptor desensitisation. These claims have specific pharmacological content: deacetylation of a prodrug, receptor occupancy, the time constants of receptor downregulation, connectivity entropy, a plasticity window. And specific pharmacological content can be written as mathematics.

This book writes that chain as mathematics and then asks, segment by segment, whether it is true. The results fall into three kinds. Some segments do not stand up conceptually: “sub-perceptual” is not a property of a dose. Some run in the opposite direction to the usual account: a saturable prodrug step blunts the peak rather than amplifying exposure, and receptor downregulation lowers the effect per dose while raising the cumulative effect. And some are mathematically unobjectionable but depend on parameters that have never been measured in humans, so the model can say what would follow if a parameter had some value, and not what actually follows.

Note

This book neither discourages nor encourages. It handles one thing: which parts of these claims follow from published evidence and mathematics, and which do not. For a practice that is controlled, thinly evidenced, and whose placebo-controlled studies are broadly null, what the book offers is a way to test it and an estimate of how large a trial that would take. Whether to do it is a question of law and personal judgement, and the book takes no part in that.

What is in this book

Chapter 1 writes receptor occupancy and the Hill relation and shows why no exposure is sub-perceptual by virtue of the receptor. Chapter 2 writes saturable prodrug conversion and reaches the book’s first reversed result. Chapter 3 writes the coupling of kinetics to effect, the effect compartment and the position of the perceptual threshold, and shows that “sub-perceptual” is a population distribution. Chapter 4 writes receptor downregulation and the “tolerance ratchet”, and reaches the second reversed result. Chapter 5 writes connectivity entropy and shows it to be indistinguishable from noise such as head motion. Chapter 6 writes the plasticity window and shows it to be a gate rather than a drive. Chapter 7 treats the Shennong Bencao Jing’s dose-finding instruction as an algorithm, compares it with modern dose-finding designs, and reads it beside Paracelsus. Chapter 8 gives a four-step checklist and a pre-registered double-blind trial.

This book sits next to several in the 5D Library; where they overlap it reviews briefly and does not repeat their programs. Volumes 5 and 17 covered metabolism and fasting; Volume 7 covered the molecules and terroir of materia medica and the three-grade classification of the Shennong Bencao Jing (continued in Chapter 7); Volume 8 covered the default mode network, 5-HT2A and the entropic brain, and established the convention this book follows of giving no doses and expressing receptor binding in dimensionless units (reviewed in Chapters 1 and 5); Volume 14 covered the dynamics of neurotransmitter systems; Volume 23 covered deliberate practice and myelination (reviewed in Chapter 6); Volume 30 covered ageing dynamics and hormesis, which is the biphasic dose-response of Chapter 7 (used there); Volume 33 covered pre-registration, power and decision rules (used in Chapter 8); Volume 34 covered psychophysics and thresholds (used in Chapter 3); and Volume 53 covered structural identifiability and negative-control outcomes (whose methods Chapters 2 and 8 reuse).

Claims corrected after checking

  1. No exposure is sub-perceptual by virtue of the receptor. Occupancy follows the Hill relation (Gesztelyi et al. 2012), whose log-log slope falls smoothly from 1 to 0 and never turns a corner or shows a threshold (Chapter 1, program p01). “Sub-perceptual” can only be imposed by perception, and Chapter 3 shows that it is a population distribution rather than a number.
  2. A saturable prodrug step blunts the peak; it does not amplify exposure. The common account has prodrug saturation making exposure “jump”. In this book’s dimensionless model that is wrong: mass balance fixes the area under the curve, almost all of the prodrug converts either way, and so AUC per unit amount is nearly constant in both regimes. What saturation changes is the shape — unsaturated, a tenfold amount raises the peak 7.84-fold and barely moves the time to peak; saturated, it raises the peak only 3.49-fold and stretches the time to peak 6.40-fold (Chapter 2, program p02).
  3. There are no published human conversion kinetics for these prodrugs. The dephosphorylation of the phosphate ester by alkaline phosphatase and related enzymes has had tissue-homogenate evidence since Horita and Weber in 1961 (Horita and Weber 1961), and the metabolism of the dephosphorylated product has been reviewed (Dinis-Oliveira 2017); psilocybin itself has human pharmacokinetic studies (Brown et al. 2017). But the literature search for this book found no published human conversion kinetics for the acetylated prodrug; reviews of tryptamines among new psychoactive substances are largely analytical chemistry and toxicological case reports (Tittarelli et al. 2015). The Michaelis constant in Chapter 2 is therefore an assumed value, not a measured one.
  4. The real obstacle is absence of data, not non-identifiability. Chapter 2, program p03 reaches a positive result: fitting an active-species concentration-time curve at a single exposure pins the Michaelis constant only to within a factor of 13, yet the predicted peak at fivefold exposure differs by only a factor of 1.31, because mass balance constrains total conversion. So structural non-identifiability is not the obstacle; the obstacle is that there is no curve to fit, in which case the peak uncertainty widens to a factor of 6.13.
  5. The time course of an effect is a property of ke0, not of the kinetics. The effect-compartment model (Sheiner et al. 1979; Holford and Sheiner 1981) shows that under an identical plasma curve, lowering ke0 from 0.3 to 0.1 changes “does it cross the perceptual threshold” from “nearly four half-lives above it” to “never” (Chapter 3, program p04). And ke0 can only be fitted to effect data; it cannot be read off concentrations.
  6. “Sub-perceptual” is a population distribution. In a synthetic population with individual variation in both exposure and threshold, no dose fraction makes the proportion noticing zero, and between 2 % and 25 % noticing there is only a 2.6-fold margin in exposure (Chapter 3, program p05). A blind therefore cannot be secured by lowering the exposure; it can only be measured.
  7. The downregulation evidence comes from high-exposure animal experiments. Repeated LSD selectively downregulates 5-HT2 receptors in rat brain (Buckholtz et al. 1990), behavioural tolerance is associated with reduced cortical 5-HT2A signalling (Gresch et al. 2005), and human tolerance was observed as early as 1956 (Isbell et al. 1956). But those exposures are far above the range discussed here, and the human recovery half-life at sub-perceptual exposure has not been measured. The tables in Chapter 4 say what would follow from a given recovery half-life, not what any schedule should be.
  8. Receptor downregulation alone cannot argue for spacing doses out. Chapter 4, program p07 reaches the second reversed result: over a fixed calendar period, a tighter schedule lowers the effect per dose while raising the cumulative effect. Both are true, and they support opposite recommendations; which matters depends on what the practice is for, and the pharmacology cannot answer that.
  9. “A rise in connectivity entropy” is indistinguishable from more noise. The entropic-brain hypothesis (Carhart-Harris et al. 2014; Carhart-Harris 2018) and the associated imaging results (Daws et al. 2022) are central to this field. Chapter 5, program p08 shows that in a Gaussian graphical model, true coupling 0.8 with independent noise and true coupling 0.6 without it give the same observed correlations and the same entropy (differing by 0.009 bits), and that raising entropy by 1 bit across 20 regions needs only about 4.6 % added noise variance. Head motion is known to produce systematic connectivity artefacts (Power et al. 2012), and how best to regress confounds is itself a research question (Ciric et al. 2017).
  10. Short-window entropy bias exceeds the effect. Chapter 5, program p09: with 12 regions and a window of 30 time points, the estimation bias is −1.978-1.978 bits, while the difference between true couplings of 0.7 and 0.5 is 2.676 bits. Bias and effect are the same size (Paninski 2003). A difference between length-matched windows, by contrast, is close to the truth at every window length, so this is a design problem and not an estimator problem.
  11. A plasticity window is a gate, not a drive. The evidence for dendritic spines and plasticity is real (Ly et al. 2018; Shao et al. 2021), direct TrkB binding supplies a mechanism (Moliner et al. 2023), and Hesselgrave and colleagues found that the synaptic and behavioural effects in mice are independent of 5-HT2 receptor activation (Hesselgrave et al. 2021) — which is inconsistent with receptor occupancy being the only route. More to the point is Nardou and colleagues’ finding that psychedelics reopen the critical period for social reward learning (Nardou et al. 2023): the window permits learning, and learning still requires input. Chapter 6, program p10 writes this as a model: with no input, the synaptic weight stays at 0 however wide the window.
  12. The latency of the input matters more than its duration. In the same model, two days of input beginning at the exposure reach 78 % of the best case; the same two days delayed to days 4–6 reach 6 % and to days 7–9 0.8 % (Chapter 6, program p10). There is a schedule that matters here, but it is the schedule of practice relative to exposure, not a dosing schedule.
  13. Placebo-controlled microdosing studies are broadly null. Szigeti and colleagues’ self-blinding citizen-science study (191 participants) found no significant difference between microdose and placebo while participants scored significantly higher when they believed they had taken the active capsule (Szigeti et al. 2021); Marschall and colleagues’ pre-registered study found no effect on emotion-related symptoms and processing (Marschall et al. 2022); Cavanna and colleagues’ double-blind placebo-controlled study reached a similar conclusion (Cavanna et al. 2022). Open-label survey studies report substantial benefit (Polito and Stevenson 2019), and reviews have already noted that the field has “more questions than answers” (Kuypers et al. 2019).
  14. A self-blinding design can produce an apparent effect with no pharmacology at all. Chapter 8, program p11: the expected apparent difference is about (2p−1)×(2p-1)\times the expectancy effect, where pp is the probability of guessing allocation correctly. At a 70 % correct-guess rate and an expectancy effect of 0.6 SD, the apparent difference is about 0.24 SD — the magnitude microdosing surveys routinely report — with no pharmacological effect needed. There is systematic-review evidence that lack of participant blinding biases results (Hróbjartsson et al. 2014).
  15. The Bencao Jing’s tenfold step is badly designed by modern standards. Chapter 7 treats the preface instruction — for a toxic drug, begin with an amount like a millet grain, stop when the illness goes, double it if it does not, then go tenfold, and take removal of the illness as the measure (Shen Nong 1998) — as an algorithm, and compares it with a 3+3 design (Storer 1989) and a continual reassessment method (O’Quigley, Pepe, and Fisher 1990). The doubling phase raises the probability of toxicity in small steps, while the final tenfold step raises it by more than all the doublings combined (Chapter 7, program p12).
  16. The language of “lightening the body and extending the years” is attached to substances now known to be toxic. The upper grade of the Shennong Bencao Jing includes cinnabar (mercuric sulphide). Modern work on mercury in traditional medicines finds that mercuric sulphide is not toxicologically equivalent to common mercurials, but that is not enough to support prolonged taking (Liu et al. 2008). The upper grade’s language therefore cannot be treated as historical evidence of safety. Paracelsus’s thesis on dose (Borzelleca 2000) stands on the same side as the Bencao Jing’s “take removal of the illness as the measure”, and the book reads them together on that basis.

How to read the marked boxes

Evidence

Evidence boxes report published findings with their sources. Human evidence, animal evidence and mechanistic speculation are written separately, as are open-label surveys and placebo-controlled trials.

Calculation

Calculation boxes give short Python programs. Each runs as printed in a standard Python 3 environment, uses only the standard library and fixes its random seeds; the typesetting pipeline for this book executes every program at build time and writes its output into the book. All concentrations, exposures and amounts in the programs are dimensionless ratios to an unspecified reference; they correspond to no mass, volume or product, and cannot be converted into any of those.

Hypothesis · not established

Hypothesis boxes are the author’s ideas, marked “not established”, with a statement of what result would show them to be wrong. A “proof” inside a model holds only inside that model.

Source text

Source text boxes quote classical works with a plain-language gloss. Every comparison across traditions is marked as an analogy.

Note

Note boxes give cautions and explain choices.

About this version

This is version 1.0.0, the first complete version: a preface and eight chapters, in Chinese and English, with 16 Python programs and 7 vector figures. The text, boxes and code were drafted with an AI writing tool from the author’s title, framework and notes; the author is responsible for reviewing and revising them and for checking every source. The occupancy curves of Chapter 1, the prodrug model and fit of Chapter 2, the effect-compartment and population models of Chapter 3, the receptor and tolerance models of Chapter 4, the Gaussian graphical model and estimator simulations of Chapter 5, the window model of Chapter 6, the algorithm comparison and biphasic curve of Chapter 7, and the planning assumptions of Chapter 8 are all the author’s models; their mathematical properties are not evidence of efficacy and not evidence of safety.

Where information-theoretic concepts are applied to imaging data, what is computed is the differential entropy of a Gaussian and the entropy of a Markov process; the book does not claim that brains have thermodynamic entropy. It contains no unsupported assertions of the form “most people will…”.

Disclosure

The author uses the works of 5D Library, including this book, as the methodological basis of his community courses, the 5D Ascension Cards (Dimensional Shift Card Decks) and the Yafu AI knowledge base, and therefore has a commercial interest in the subject of this book. The group also operates ketohackers.com and nadplusnadplus.com, two health-education sites adjacent to this book’s metabolic and plasticity themes; this book links to neither and mentions no product. The book promotes no course, card deck, substance or service, gives no dose, source, route or course of use, and explicitly does not recommend that anyone use any substance it discusses; the Chapter 8 trial is designed to be run and analysed by researchers independent of the author’s business, in a jurisdiction where the required regulatory authorisation has been obtained, and does not recruit from the author’s community, students or customers; all the code and the study protocol are published openly for anyone to check. The author provides no medical services and sells no substance, device, supplement or test.

References

Borzelleca, Joseph F. 2000. “Paracelsus: Herald of Modern Toxicology.” Toxicological Sciences 53 (1): 2–4. https://doi.org/10.1093/toxsci/53.1.2.
Brown, Randall T., Christopher R. Nicholas, Nicholas V. Cozzi, Michele C. Gassman, Karen M. Cooper, Daniel Muller, Chantelle D. Thomas, et al. 2017. “Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults.” Clinical Pharmacokinetics 56 (12): 1543–54. https://doi.org/10.1007/s40262-017-0540-6.
Buckholtz, Neil S., Da Fu Zhou, Daniel X. Freedman, and William Z. Potter. 1990. “Lysergic Acid Diethylamide (LSD) Administration Selectively Downregulates Serotonin2_2 Receptors in Rat Brain.” Neuropsychopharmacology 3 (2): 137–48.
Carhart-Harris, Robin L. 2018. “The Entropic Brain — Revisited.” Neuropharmacology 142: 167–78. https://doi.org/10.1016/j.neuropharm.2018.03.010.
Carhart-Harris, Robin L., Robert Leech, Peter J. Hellyer, Murray Shanahan, Amanda Feilding, Enzo Tagliazucchi, Dante R. Chialvo, and David Nutt. 2014. “The Entropic Brain: A Theory of Conscious States Informed by Neuroimaging Research with Psychedelic Drugs.” Frontiers in Human Neuroscience 8: 20. https://doi.org/10.3389/fnhum.2014.00020.
Cavanna, Federico, Stephanie Muller, Laura Alethia de la Fuente, Federico Zamberlan, Matias Palmucci, Lucie Janeckova, Martin Kuchar, Carla Pallavicini, and Enzo Tagliazucchi. 2022. “Microdosing with Psilocybin Mushrooms: A Double-Blind Placebo-Controlled Study.” Translational Psychiatry 12: 307. https://doi.org/10.1038/s41398-022-02039-0.
Ciric, Rastko, Daniel H. Wolf, Jonathan D. Power, David R. Roalf, Graham L. Baum, Kosha Ruparel, Russell T. Shinohara, et al. 2017. “Benchmarking of Participant-Level Confound Regression Strategies for the Control of Motion Artifact in Studies of Functional Connectivity.” NeuroImage 154: 174–87. https://doi.org/10.1016/j.neuroimage.2017.03.020.
Daws, Richard E., Christopher Timmermann, Bruna Giribaldi, James D. Sexton, Matthew B. Wall, David Erritzoe, Leor Roseman, David Nutt, and Robin Carhart-Harris. 2022. “Increased Global Integration in the Brain After Psilocybin Therapy for Depression.” Nature Medicine 28: 844–51. https://doi.org/10.1038/s41591-022-01744-z.
Dinis-Oliveira, Ricardo Jorge. 2017. “Metabolism of Psilocybin and Psilocin: Clinical and Forensic Toxicological Relevance.” Drug Metabolism Reviews 49 (1): 84–91. https://doi.org/10.1080/03602532.2016.1278228.
Gesztelyi, Rudolf, Judit Zsuga, Adam Kemeny-Beke, Balazs Varga, Bela Juhasz, and Arpad Tosaki. 2012. “The Hill Equation and the Origin of Quantitative Pharmacology.” Archive for History of Exact Sciences 66: 427–38. https://doi.org/10.1007/s00407-012-0098-5.
Government of Malaysia. 2006. “Dangerous Drugs Act 1952 (Act 234).” Revised consolidated text; Psilocybine and Psilocine are listed in the First Schedule, Part III.
Gresch, Paul J., Randy L. Smith, Jeffrey T. McCracken, Robert J. Barrett, and Elaine Sanders-Bush. 2005. “Behavioral Tolerance to Lysergic Acid Diethylamide Is Associated with Reduced Serotonin-2A Receptor Signaling in Rat Cortex.” Neuropsychopharmacology 30 (9): 1693–1702. https://doi.org/10.1038/sj.npp.1300711.
Hesselgrave, Natalie, Timothy A. Troppoli, Andreas B. Wulff, Anthony B. Cole, and Scott M. Thompson. 2021. “Harnessing Psilocybin: Antidepressant-Like Behavioral and Synaptic Actions of Psilocybin Are Independent of 5-HT2R Activation in Mice.” Proceedings of the National Academy of Sciences 118 (17): e2022489118. https://doi.org/10.1073/pnas.2022489118.
Holford, Nicholas H. G., and Lewis B. Sheiner. 1981. “Understanding the Dose-Effect Relationship: Clinical Application of Pharmacokinetic-Pharmacodynamic Models.” Clinical Pharmacokinetics 6 (6): 429–53. https://doi.org/10.2165/00003088-198106060-00002.
Horita, Akira, and L. J. Weber. 1961. “The Enzymic Dephosphorylation and Oxidation of Psilocybin and Psilocin by Mammalian Tissue Homogenates.” Biochemical Pharmacology 7: 47–54. https://doi.org/10.1016/0006-2952(61)90124-1.
Hróbjartsson, Asbjørn, Frida Emanuelsson, Ann Sofia Skou Thomsen, Jørgen Hilden, and Stig Brorson. 2014. “Bias Due to Lack of Patient Blinding in Clinical Trials: A Systematic Review of Trials Randomizing Patients to Blind and Nonblind Sub-Studies.” International Journal of Epidemiology 43 (4): 1272–83. https://doi.org/10.1093/ije/dyu115.
Isbell, Harris, R. E. Belleville, H. F. Fraser, A. Wikler, and C. R. Logan. 1956. “Studies on Lysergic Acid Diethylamide (LSD-25): Effects in Former Morphine Addicts and Development of Tolerance During Chronic Intoxication.” AMA Archives of Neurology and Psychiatry 76 (5): 468–78. https://doi.org/10.1001/archneurpsyc.1956.02330290012002.
Kuypers, Kim P. C., Lionel Ng, David Erritzoe, Gitte M. Knudsen, Charles D. Nichols, David E. Nichols, Luca Pani, Anais Soula, and David Nutt. 2019. “Microdosing Psychedelics: More Questions Than Answers? An Overview and Suggestions for Future Research.” Journal of Psychopharmacology 33 (9): 1039–57. https://doi.org/10.1177/0269881119857204.
Liu, Jie, Jing-Zhen Shi, Li-Mei Yu, Robert A. Goyer, and Michael P. Waalkes. 2008. “Mercury in Traditional Medicines: Is Cinnabar Toxicologically Similar to Common Mercurials?” Experimental Biology and Medicine 233 (7): 810–17. https://doi.org/10.3181/0712-MR-336.
Ly, Calvin, Alexandra C. Greb, Lindsay P. Cameron, Jonathan M. Wong, Eden V. Barragan, Paige C. Wilson, Kyle F. Burbach, et al. 2018. “Psychedelics Promote Structural and Functional Neural Plasticity.” Cell Reports 23 (11): 3170–82. https://doi.org/10.1016/j.celrep.2018.05.022.
Marschall, Josephine, Gabor Fejer, Pascal Lempe, Luisa Prochazkova, Martin Kuchar, Katerina Hajkova, and Michiel van Elk. 2022. “Psilocybin Microdosing Does Not Affect Emotion-Related Symptoms and Processing: A Preregistered Field and Lab-Based Study.” Journal of Psychopharmacology 36 (1): 97–113. https://doi.org/10.1177/02698811211050556.
Moliner, Rafael, Mykhailo Girych, Cecilia A. Brunello, Vera Kovaleva, Caroline Biojone, Giray Enkavi, Lina Antenucci, et al. 2023. “Psychedelics Promote Plasticity by Directly Binding to BDNF Receptor TrkB.” Nature Neuroscience 26: 1032–41. https://doi.org/10.1038/s41593-023-01316-5.
Nardou, Romain, Eastman Sawyer, Young Jun Song, Makenzie Wilkinson, Yasmin Padovan-Hernandez, Junia Lara de Deus, Noelle Wright, et al. 2023. “Psychedelics Reopen the Social Reward Learning Critical Period.” Nature 618: 790–98. https://doi.org/10.1038/s41586-023-06204-3.
O’Quigley, John, Margaret Pepe, and Lloyd Fisher. 1990. “Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer.” Biometrics 46 (1): 33–48. https://doi.org/10.2307/2531628.
Paninski, Liam. 2003. “Estimation of Entropy and Mutual Information.” Neural Computation 15 (6): 1191–1253. https://doi.org/10.1162/089976603321780272.
Polito, Vince, and Richard J. Stevenson. 2019. “A Systematic Study of Microdosing Psychedelics.” PLOS ONE 14 (2): e0211023. https://doi.org/10.1371/journal.pone.0211023.
Power, Jonathan D., Kelly A. Barnes, Abraham Z. Snyder, Bradley L. Schlaggar, and Steven E. Petersen. 2012. “Spurious but Systematic Correlations in Functional Connectivity MRI Networks Arise from Subject Motion.” NeuroImage 59 (3): 2142–54. https://doi.org/10.1016/j.neuroimage.2011.10.018.
Shao, Ling-Xiao, Clara Liao, Ian Gregg, Pasha A. Davoudian, Neil K. Savalia, Kristina Delagarza, and Alex C. Kwan. 2021. “Psilocybin Induces Rapid and Persistent Growth of Dendritic Spines in Frontal Cortex in Vivo.” Neuron 109 (16): 2535–44. https://doi.org/10.1016/j.neuron.2021.06.008.
Sheiner, Lewis B., Donald R. Stanski, Samuel Vozeh, Ronald D. Miller, and Jerry Ham. 1979. “Simultaneous Modeling of Pharmacokinetics and Pharmacodynamics: Application to d-Tubocurarine.” Clinical Pharmacology and Therapeutics 25 (3): 358–71. https://doi.org/10.1002/cpt1979253358.
Shen Nong. 1998. The Divine Farmer’s Materia Medica: A Translation of the Shen Nong Ben Cao Jing. The Three-Grade Classification and the Escalation Instruction Appear in the Preface. Translated by Shou-zhong Yang. Boulder, Colorado: Blue Poppy Press.
Storer, Barry E. 1989. “Design and Analysis of Phase I Clinical Trials.” Biometrics 45 (3): 925–37. https://doi.org/10.2307/2531693.
Szigeti, Balázs, Laura Kartner, Allan Blemings, Fernando Rosas, Amanda Feilding, David J. Nutt, Robin L. Carhart-Harris, and David Erritzoe. 2021. “Self-Blinding Citizen Science to Explore Psychedelic Microdosing.” eLife 10: e62878. https://doi.org/10.7554/eLife.62878.
Therapeutic Goods Administration, Australia. 2023. “Change to Classification of Psilocybin and MDMA to Enable Prescribing by Authorised Psychiatrists.” Regulatory decision effective 1 July 2023.
Tittarelli, Roberta, Giulio Mannocchi, Flaminia Pantano, and Francesco Saverio Romolo. 2015. “Recreational Use, Analysis and Toxicity of Tryptamines.” Current Neuropharmacology 13 (1): 26–46. https://doi.org/10.2174/1570159X13666141210222409.

Fan, Y. (2026). Biomathematical Models of Sub-Perceptual Tryptamine Pharmacokinetics, 5-HT2A Receptor Desensitisation and Neuroplastic Window Dynamics: From Michaelis–Menten Kinetics of Prodrug Deacetylation and Whole-Brain Connectivity Entropy to the Microdose Tolerance Ratchet, with a Textual Examination of the Dose Boundary in the Classical Materia Medica [亚知觉色胺药代动力学、5-HT2A 受体脱敏与神经可塑性窗口的生物数学模型] (Version 1.0.0). 5D Library. https://doi.org/10.5281/zenodo.24019347 · Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0).